| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
|
Lancet Oncol
|
2014
|
5.89
|
|
2
|
Novel therapies for metastatic castrate-resistant prostate cancer.
|
J Natl Cancer Inst
|
2011
|
1.98
|
|
3
|
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
|
Eur Urol
|
2014
|
1.44
|
|
4
|
Immunotherapy for the treatment of prostate cancer.
|
Nat Rev Clin Oncol
|
2011
|
1.12
|
|
5
|
Overview of the latest treatments for castration-resistant prostate cancer.
|
Nat Rev Urol
|
2013
|
1.12
|
|
6
|
Trial watch: DNA vaccines for cancer therapy.
|
Oncoimmunology
|
2013
|
1.11
|
|
7
|
Prostate cancer immunotherapy.
|
Clin Cancer Res
|
2011
|
1.11
|
|
8
|
Castration-resistant prostate cancer: latest evidence and therapeutic implications.
|
Ther Adv Med Oncol
|
2014
|
1.11
|
|
9
|
Current status of immunological therapies for prostate cancer.
|
Curr Opin Urol
|
2010
|
1.06
|
|
10
|
Molecular pathways and targets in prostate cancer.
|
Oncotarget
|
2014
|
1.00
|
|
11
|
Therapeutic cancer vaccines: past, present, and future.
|
Adv Cancer Res
|
2013
|
0.99
|
|
12
|
Prostate cancer vaccines: Update on clinical development.
|
Oncoimmunology
|
2013
|
0.98
|
|
13
|
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
|
Ther Adv Med Oncol
|
2013
|
0.97
|
|
14
|
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
|
Cancer Immunol Immunother
|
2011
|
0.97
|
|
15
|
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
|
Ther Adv Urol
|
2014
|
0.96
|
|
16
|
Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
|
Nat Rev Urol
|
2012
|
0.93
|
|
17
|
Targeting the adaptive molecular landscape of castration-resistant prostate cancer.
|
EMBO Mol Med
|
2015
|
0.93
|
|
18
|
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
|
Front Immunol
|
2014
|
0.92
|
|
19
|
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
|
Clin Cancer Res
|
2013
|
0.92
|
|
20
|
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
|
Curr Opin Oncol
|
2012
|
0.92
|
|
21
|
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
|
Viruses
|
2015
|
0.92
|
|
22
|
Exploiting synergy: immune-based combinations in the treatment of prostate cancer.
|
Front Oncol
|
2014
|
0.91
|
|
23
|
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
24
|
Immunotherapy for prostate cancer: recent developments and future challenges.
|
Cancer Metastasis Rev
|
2014
|
0.90
|
|
25
|
Antigen-specific vaccines for cancer treatment.
|
Hum Vaccin Immunother
|
2014
|
0.89
|
|
26
|
Update on prostate cancer vaccines.
|
Cancer J
|
2011
|
0.88
|
|
27
|
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
|
Int J Mol Sci
|
2013
|
0.88
|
|
28
|
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.
|
Ther Adv Vaccines
|
2014
|
0.86
|
|
29
|
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
|
Oncology (Williston Park)
|
2015
|
0.85
|
|
30
|
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.
|
Oncoimmunology
|
2014
|
0.84
|
|
31
|
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
|
Asian J Androl
|
2014
|
0.84
|
|
32
|
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
|
Cancer J
|
2013
|
0.84
|
|
33
|
Emerging molecularly targeted therapies in castration refractory prostate cancer.
|
Prostate Cancer
|
2013
|
0.83
|
|
34
|
Trial watch: Naked and vectored DNA-based anticancer vaccines.
|
Oncoimmunology
|
2015
|
0.83
|
|
35
|
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
|
Ann Oncol
|
2015
|
0.82
|
|
36
|
Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.
|
Drug Des Devel Ther
|
2014
|
0.82
|
|
37
|
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
|
Curr Opin Oncol
|
2015
|
0.82
|
|
38
|
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.
|
Hum Vaccin Immunother
|
2014
|
0.81
|
|
39
|
Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.
|
Oncoimmunology
|
2014
|
0.81
|
|
40
|
Current status of immunological approaches for the treatment of prostate cancer.
|
Curr Opin Urol
|
2012
|
0.81
|
|
41
|
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
|
Ther Adv Med Oncol
|
2016
|
0.81
|
|
42
|
Emerging targeted therapies for castration-resistant prostate cancer.
|
Front Endocrinol (Lausanne)
|
2012
|
0.81
|
|
43
|
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.
|
Ther Clin Risk Manag
|
2014
|
0.80
|
|
44
|
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
|
J Immunother Cancer
|
2014
|
0.80
|
|
45
|
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
|
Clin Med Insights Oncol
|
2012
|
0.80
|
|
46
|
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
|
Curr Treat Options Oncol
|
2014
|
0.79
|
|
47
|
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.
|
Hum Vaccin Immunother
|
2014
|
0.78
|
|
48
|
Unmet needs in the prediction and detection of metastases in prostate cancer.
|
Oncologist
|
2013
|
0.78
|
|
49
|
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine.
|
Clin Genitourin Cancer
|
2011
|
0.78
|
|
50
|
Drug discovery in advanced prostate cancer: translating biology into therapy.
|
Nat Rev Drug Discov
|
2016
|
0.78
|
|
51
|
DNA vaccination for prostate cancer: key concepts and considerations.
|
Cancer Nanotechnol
|
2015
|
0.78
|
|
52
|
Immunobiology and immunotherapy in genitourinary malignancies.
|
Ann Transl Med
|
2016
|
0.78
|
|
53
|
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?
|
Oncology (Williston Park)
|
2014
|
0.78
|
|
54
|
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
|
Cancer Immunol Res
|
2016
|
0.78
|
|
55
|
Immunotherapy for prostate cancer: False promises or true hope?
|
Cancer
|
2016
|
0.78
|
|
56
|
Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances.
|
J Natl Compr Canc Netw
|
2013
|
0.77
|
|
57
|
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
|
Semin Oncol
|
2015
|
0.77
|
|
58
|
Immunotherapy for prostate cancer enters its golden age.
|
Clin Med Insights Oncol
|
2012
|
0.77
|
|
59
|
Immune Therapy for Prostate Cancer.
|
Cancer J
|
2016
|
0.76
|
|
60
|
Development of PROSTVAC immunotherapy in prostate cancer.
|
Future Oncol
|
2015
|
0.76
|
|
61
|
Immunotherapy and immune evasion in prostate cancer.
|
Cancers (Basel)
|
2013
|
0.76
|
|
62
|
New clinical advances in immunotherapy for the treatment of solid tumours.
|
Immunology
|
2015
|
0.76
|
|
63
|
MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
|
PLoS One
|
2016
|
0.75
|
|
64
|
The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.
|
P T
|
2012
|
0.75
|
|
65
|
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.
|
Cancers (Basel)
|
2012
|
0.75
|
|
66
|
A Perspective of Immunotherapy for Prostate Cancer.
|
Cancers (Basel)
|
2016
|
0.75
|
|
67
|
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
|
Immunotargets Ther
|
2014
|
0.75
|